Changes in epithelial lining fluid albumin associated with smoking and interstitial lung disease

Albumin is an important plasma protein which is useful in the assessment of in vivo membrane permeability in the lung. In subjects with interstitial lung disease (ILD) the relationship between albumin recovered from bronchoalveolar lavage (BAL) and other markers of inflammatory activity may provide useful information of the pathogenesis of the disease process. Unfortunately, its measurement is hampered by the variable dilution in BAL fluid. In this study, urea was used as a marker of epithelial lining fluid (ELF) dilution allowing the calculation of an apparent epithelial lining fluid volume and adjusted albumin content. We examined the relationship between ELF albumin content and BAL cell counts, immunoglobulin content, respiratory function tests and gallium lung scans in both smokers and nonsmokers with and without interstitial lung disease. Forty seven subjects with connective tissue disease and interstitial lung disease and 51 subjects with either connective tissue disease but no pulmonary involvement or non pulmonary malignancy (18 current smokers) underwent BAL, gallium lung scans and respiratory function tests. The subjects with ILD were further subdivided into those with active ILD or bronchiolitis using cluster analysis. In smokers without ILD an increased ELF volume and a decrease in ELF albumin were found. Increased ELF albumin was related to increased age. In subjects with ILD, increased albumin was strongly correlated with increased BAL lymphocyte absolute and differential counts, which overwhelmed any age or smoking effect. These findings suggest a possible causal relationship between lung vascular permeability and lymphocyte numbers in subjects with interstitial lung disease and reinforce the need to consider smoking and age as confounding factors in BAL analysis.

This article has been cited by other articles:

				W. J. Piotrowski, A. Antczak, J. Marczak, A. Nawrocka, Z. Kurmanowska, and P. Gorski Eicosanoids in Exhaled Breath Condensate and BAL Fluid of Patients With Sarcoidosis Chest, August 1, 2007; 132(2): 589 - 596. [Abstract] [Full Text] [PDF]

				E. Kriegova, C. Melle, V. Kolek, B. Hutyrova, F. Mrazek, A. Bleul, R. M. du Bois, F. von Eggeling, and M. Petrek Protein Profiles of Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1145 - 1154. [Abstract] [Full Text] [PDF]

				S. Murin, K. E. Pinkerton, N. E. Hubbard, and K. Erickson The Effect of Cigarette Smoke Exposure on Pulmonary Metastatic Disease in a Murine Model of Metastatic Breast Cancer Chest, April 1, 2004; 125(4): 1467 - 1471. [Abstract] [Full Text] [PDF]

				M. Robin, P. Dong, C. Hermans, A. Bernard, A.D. Bersten, and I.R. Doyle Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects Eur. Respir. J., November 1, 2002; 20(5): 1152 - 1161. [Abstract] [Full Text] [PDF]

				C. Hermans, M. Petrek, V. Kolek, B. Weynand, T. Pieters, M. Lambert, and A. Bernard Serum Clara cell protein (CC16), a marker of the integrity of the air-blood barrier in sarcoidosis Eur. Respir. J., September 1, 2001; 18(3): 507 - 514. [Abstract] [Full Text] [PDF]

				S. Murin and J. Inciardi Cigarette Smoking and the Risk of Pulmonary Metastasis From Breast Cancer Chest, June 1, 2001; 119(6): 1635 - 1640. [Abstract] [Full Text] [PDF]

				A. Ishizaka, N. Hasegawa, K. Nakamura, Y. Takagi, M. Takano, K. Yamaguchi, and A. Kubo Usefulness of Pulmonary Vascular Leakiness Assessment in Interstitial Pneumonitis Chest, May 1, 2001; 119(5): 1455 - 1460. [Abstract] [Full Text] [PDF]

				Y. Inoue, E. Barker, E. Daniloff, N. Kohno, K. Hiwada, and L. S. Newman Pulmonary Epithelial Cell Injury and Alveolar-Capillary Permeability in Berylliosis Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 109 - 115. [Abstract] [Full Text]